{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T01:36:01Z","timestamp":1794274561655,"version":"4.9.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,4,1]],"date-time":"2022-04-01T00:00:00Z","timestamp":1648771200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T00:00:00Z","timestamp":1634774400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2022,4]]},"DOI":"10.1016\/j.ophtha.2021.10.017","type":"journal-article","created":{"date-parts":[[2021,10,21]],"date-time":"2021-10-21T16:43:07Z","timestamp":1634834587000},"page":"438-449","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":174,"title":["Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment"],"prefix":"10.1016","volume":"129","author":[{"given":"Raymond S.","family":"Douglas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George J.","family":"Kahaly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoaib","family":"Ugradar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heike","family":"Elflein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina A.","family":"Ponto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian T.","family":"Fowler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roger","family":"Dailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald J.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jade","family":"Schiffman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2036-5640","authenticated-orcid":false,"given":"Rosa","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Wester","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy Patel","family":"Jain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claudio","family":"Marcocci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Marin\u00f2","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5211-6342","authenticated-orcid":false,"given":"Alessandro","family":"Antonelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anja","family":"Eckstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dagmar","family":"F\u00fchrer-Sakel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0276-0367","authenticated-orcid":false,"given":"Mario","family":"Salvi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saba","family":"Sile","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Megan","family":"Francis-Sedlak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J.","family":"Holt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry J.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2021.10.017_bib1","first-page":"477","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley","year":"1994","journal-title":"Trans Am Ophthalmol Soc"},{"issue":"1","key":"10.1016\/j.ophtha.2021.10.017_bib2","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1136\/bjo.88.1.75","article-title":"Assessing quality of life in Australian patients with Graves\u2019 ophthalmopathy","volume":"88","author":"Park","year":"2004","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2021.10.017_bib3","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ajo.2011.02.018","article-title":"Quality of life in a German Graves orbitopathy population","volume":"152","author":"Ponto","year":"2011","journal-title":"Am J Ophthalmol"},{"issue":"9","key":"10.1016\/j.ophtha.2021.10.017_bib4","doi-asserted-by":"crossref","first-page":"1407","DOI":"10.1089\/thy.2014.0037","article-title":"What are the psychosocial outcomes of treatment for thyroid eye disease? A systematic review","volume":"24","author":"Wickwar","year":"2014","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ophtha.2021.10.017_bib5","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1210\/jc.2012-3119","article-title":"Public health relevance of Graves\u2019 orbitopathy","volume":"98","author":"Ponto","year":"2013","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"12","key":"10.1016\/j.ophtha.2021.10.017_bib6","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1089\/thy.2017.0365","article-title":"Death by suicide\u00a0in Graves\u2019 disease and Graves\u2019 orbitopathy: a nationwide Danish register study","volume":"27","author":"Ferlov-Schwensen","year":"2017","journal-title":"Thyroid"},{"issue":"1","key":"10.1016\/j.ophtha.2021.10.017_bib7","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1210\/jcem.87.1.8164","article-title":"Orbital fibroblast heterogeneity may determine the clinical presentation of thyroid-associated ophthalmopathy","volume":"87","author":"Smith","year":"2002","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ophtha.2021.10.017_bib8","doi-asserted-by":"crossref","first-page":"4397","DOI":"10.4049\/jimmunol.181.6.4397","article-title":"Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves\u2019 disease","volume":"181","author":"Tsui","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"8","key":"10.1016\/j.ophtha.2021.10.017_bib9","doi-asserted-by":"crossref","first-page":"5768","DOI":"10.4049\/jimmunol.181.8.5768","article-title":"B\u00a0cells from patients with Graves\u2019 disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis","volume":"181","author":"Douglas","year":"2008","journal-title":"J\u00a0Immunol"},{"issue":"4","key":"10.1016\/j.ophtha.2021.10.017_bib10","doi-asserted-by":"crossref","first-page":"E625","DOI":"10.1210\/jc.2013-3977","article-title":"Regulation of IL-1 receptor antagonist by TSH in fibrocytes and orbital fibroblasts","volume":"99","author":"Li","year":"2014","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ophtha.2021.10.017_bib11","doi-asserted-by":"crossref","first-page":"2615","DOI":"10.1167\/iovs.18-23951","article-title":"CD34-orbital fibroblasts from patients with thyroid-associated ophthalmopathy modulate TNF-alpha expression in CD34+ fibroblasts and fibrocytes","volume":"59","author":"Lu","year":"2018","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"9","key":"10.1016\/j.ophtha.2021.10.017_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0075100","article-title":"Thyrotropin regulates IL-6 expression in CD34+ fibrocytes: clear delineation of its cAMP-independent actions","volume":"8","author":"Raychaudhuri","year":"2013","journal-title":"PLoS One"},{"issue":"31","key":"10.1016\/j.ophtha.2021.10.017_bib13","doi-asserted-by":"crossref","first-page":"22910","DOI":"10.1074\/jbc.M703597200","article-title":"Differentiation of human circulating fibrocytes as mediated by transforming growth factor-beta and peroxisome proliferator-activated receptor gamma","volume":"282","author":"Hong","year":"2007","journal-title":"J\u00a0Biol Chem"},{"issue":"7","key":"10.1016\/j.ophtha.2021.10.017_bib14","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.4049\/jimmunol.1900434","article-title":"Slit2 may underlie divergent induction by thyrotropin of IL-23 and IL-12 in human fibrocytes","volume":"204","author":"Fernando","year":"2020","journal-title":"J\u00a0Immunol"},{"issue":"1","key":"10.1016\/j.ophtha.2021.10.017_bib15","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1210\/clinem\/dgaa684","article-title":"Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: potential relevance to thyroid-associated ophthalmopathy","volume":"106","author":"Fernando","year":"2021","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.ophtha.2021.10.017_bib16","doi-asserted-by":"crossref","first-page":"4336","DOI":"10.1210\/en.2015-1399","article-title":"Pentraxin-3 is a TSH-inducible protein in human fibrocytes and orbital fibroblasts","volume":"156","author":"Wang","year":"2015","journal-title":"Endocrinology"},{"issue":"1","key":"10.1016\/j.ophtha.2021.10.017_bib17","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1007\/s13317-011-0025-9","article-title":"In\u00a0vivo effects of a human thyroid-stimulating monoclonal autoantibody (M22) and a human thyroid-blocking autoantibody (K1-70)","volume":"3","author":"Furmaniak","year":"2011","journal-title":"Auto Immun Highlights"},{"issue":"9","key":"10.1016\/j.ophtha.2021.10.017_bib18","doi-asserted-by":"crossref","first-page":"2607","DOI":"10.1038\/s41433-020-01297-w","article-title":"Teprotumumab for non-inflammatory thyroid eye disease (TED): evidence for increased IGF-1R expression","volume":"35","author":"Ugradar","year":"2020","journal-title":"Eye (Lond)"},{"issue":"18","key":"10.1016\/j.ophtha.2021.10.017_bib19","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith","year":"2017","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.ophtha.2021.10.017_bib20","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","article-title":"Teprotumumab for the treatment of active thyroid eye disease","volume":"382","author":"Douglas","year":"2020","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.ophtha.2021.10.017_bib21","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","article-title":"Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease","volume":"106","author":"Jain","year":"2022","journal-title":"Br J Ophthalmol"},{"issue":"7","key":"10.1016\/j.ophtha.2021.10.017_bib22","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1136\/bjo.82.7.773","article-title":"Development of a disease specific quality of life questionnaire for patients with Graves\u2019 ophthalmopathy: the GO-QOL","volume":"82","author":"Terwee","year":"1998","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"10.1016\/j.ophtha.2021.10.017_bib23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/BF03345275","article-title":"Effects of Graves\u2019 ophthalmopathy on quality of life","volume":"27","author":"Wiersinga","year":"2004","journal-title":"J\u00a0Endocrinol Invest"},{"issue":"6","key":"10.1016\/j.ophtha.2021.10.017_bib24","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/S2213-8587(21)00056-5","article-title":"Teprotumumab for patients with active thyroid eye disease: a pooled data analysis, subgroup analyses, and off-treatment follow-up results from two randomised, double-masked, placebo-controlled, multicentre trials","volume":"9","author":"Kahaly","year":"2021","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"13","key":"10.1016\/j.ophtha.2021.10.017_bib25","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1093\/jnci\/djs258","article-title":"Insulin-like growth factor receptor inhibitors: baby or the bathwater?","volume":"104","author":"Yee","year":"2012","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"19","key":"10.1016\/j.ophtha.2021.10.017_bib26","doi-asserted-by":"crossref","first-page":"5834","DOI":"10.1158\/1078-0432.CCR-07-1118","article-title":"Phase I dose escalation study of the anti insulin-like growth factor-I receptor monoclonal antibody CP-751,871 in patients with refractory solid tumors","volume":"13","author":"Haluska","year":"2007","journal-title":"Clin Cancer Res"},{"issue":"1","key":"10.1016\/j.ophtha.2021.10.017_bib27","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1530\/JOE-13-0306","article-title":"IGF1R blockade with ganitumab results in systemic effects on the GH-IGF axis in mice","volume":"221","author":"Moody","year":"2014","journal-title":"J\u00a0Endocrinol"},{"issue":"6","key":"10.1016\/j.ophtha.2021.10.017_bib28","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1111\/bcp.12228","article-title":"The adverse events profile of anti-IGF-1R monoclonal antibodies in cancer therapy","volume":"77","author":"Ma","year":"2014","journal-title":"Br J Clin Pharmacol"},{"issue":"6","key":"10.1016\/j.ophtha.2021.10.017_bib29","doi-asserted-by":"crossref","first-page":"S168","DOI":"10.1016\/j.eprac.2021.04.823","article-title":"Thyroid eye disease in the United States: data from emergency department visits and hospitalizations","volume":"27","author":"Singh","year":"2021","journal-title":"Endocrine Practice"},{"key":"10.1016\/j.ophtha.2021.10.017_bib30","doi-asserted-by":"crossref","first-page":"A843","DOI":"10.1210\/jendso\/bvab048.1720","article-title":"Severe thyroid eye disease in the US: a national perspective","volume":"5","author":"Singh","year":"2021","journal-title":"J\u00a0Endocr Soc"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021008186?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642021008186?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T14:11:43Z","timestamp":1758982303000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642021008186"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["S0161642021008186"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2022,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Teprotumumab Efficacy, Safety, and Durability in Longer-Duration Thyroid Eye Disease and Re-treatment","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2021.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}